Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $576.8 million.

  • Centessa Pharmaceuticals' Liabilities and Shareholders Equity fell 26.47% to $448.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 20.51%. This contributed to the annual value of $576.8 million for FY2024, which is 60.11% up from last year.
  • According to the latest figures from FY2024, Centessa Pharmaceuticals' Liabilities and Shareholders Equity is $576.8 million, which was up 60.11% from $360.2 million recorded in FY2023.
  • Centessa Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $576.8 million during FY2024, with a 5-year trough of $360.2 million in FY2023.
  • In the last 3 years, Centessa Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $444.3 million in 2022 and averaged $460.5 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Liabilities and Shareholders Equity decreased by 18.92% in 2023, and later surged by 60.11% in 2024.
  • Centessa Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $444.3 million in 2022, then dropped by 18.92% to $360.2 million in 2023, then spiked by 60.11% to $576.8 million in 2024.